课题基金 / 基金详情

SAMHD1-mediated regulation of HIV-1 innate immunity and viral gene expression

SAMHD1-mediated regulation of HIV-1 innate immunity and viral gene expression
SAMHD1介导的HIV-1先天免疫和病毒基因表达的调节
批准号:
10025843
负责人:
Li Wu
金额:
$47.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-01 至 2024-02-29

项目摘要

项目成果

Li Wu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract A critical barrier to developing a cure for HIV-1 infection is the long-lived viral reservoir in cells due to viral latency. Many host proteins regulate HIV-1 gene expression and viral latency. By reducing intracellular dNTP levels, the host protein SAMHD1 inhibits HIV-1 replication in myeloid cells and resting CD4+ T-cells, cell types that are important for HIV-1 latency. Patients with homozygous SAMHD1 mutations experience autoimmune diseases, but the functions and mechanisms of SAMHD1 in modulating inflammation and immunity remain unclear. Despite extensive studies of the mechanisms underlying SAMHD1-mediated restriction of virus replication, it is unknown whether and how SAMHD1 regulates antiviral innate immune responses. Here, we aim to address two key questions: (a) What are the mechanisms of SAMHD1 in modulating the innate immune response to HIV-1 infection? (b) How does SAMHD1 affect HIV-1 gene expression? Our new findings demonstrated that SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting nuclear factor-kappa B (NF-κB) activation and type I interferon (IFN-I) induction through distinct mechanisms. We discovered that SAMHD1 interacts with key proteins in the NF-κB and IFN-I pathways, allowing it to act as a multifaceted repressor of innate immune signaling. We also found that SAMHD1 impairs HIV-1 gene expression and reactivation of viral latency in primary CD4+ T-cells. NF-κB is critical for HIV-1 gene transcription and transcriptional inhibition of viral gene expression is the main mechanism of HIV-1 latency. Our central hypothesis is that SAMHD1 modulates HIV-1 antiviral immunity and viral gene expression by suppressing NF-κB activation, IFN-I induction, and viral transcription. We designed three specific aims to test this hypothesis. Aim 1. Elucidate the mechanisms by which SAMHD1 suppresses NF-κB activation in HIV-1 infection; Aim 2. Define the mechanisms by which SAMHD1 suppresses IFN-I induction during HIV-1 infection; Aim 3. Investigate the mechanisms by which SAMHD1 impairs reactivation of HIV-1 gene expression. Overall impact. These studies will reveal novel physiological functions of SAMHD1 during HIV-1 infection of primary target cells, which are beyond its known function in restricting virus replication. Furthermore, our interdisciplinary studies will yield new results to fundamentally enhance our mechanistic understanding of SAMHD1 in regulating HIV-1 infection, viral gene expression, and anti-HIV innate immune responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting HIV-1 RNA modifications in latently infected CD4+ T cells for therapeutic development
  • 批准号:
    10596144
  • 项目类别:
  • 资助金额:
    $69.99万
  • 财政年份:
    2022
  • 负责人:
    Li Wu
  • 依托单位:
Targeting HIV-1 RNA modifications in latently infected CD4+ T cells for therapeutic development
  • 批准号:
    10462273
  • 项目类别:
  • 资助金额:
    $75.13万
  • 财政年份:
    2022
  • 负责人:
    Li Wu
  • 依托单位:
Epitranscriptomic m6A profile of SARS-CoV-2-infected human lung epithelial cells
  • 批准号:
    10412132
  • 项目类别:
  • 资助金额:
    $23.18万
  • 财政年份:
    2021
  • 负责人:
    Li Wu
  • 依托单位:
Epitranscriptomic m6A profile of SARS-CoV-2-infected human lung epithelial cells
  • 批准号:
    10297640
  • 项目类别:
  • 资助金额:
    $19.31万
  • 财政年份:
    2021
  • 负责人:
    Li Wu
  • 依托单位:
国内基金
海外基金
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
基于NLRP3/IL-1β信号探讨α7nAChR介导巨噬细胞—心肌细胞互作在Aβ诱导房颤心房重构中的作用及机制研究
Tom1L1在胞内体蛋白分选机制中功能的研究
  • 批准号:
    31171289
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2011
  • 负责人:
    刘宁生
  • 依托单位:
溶酶体依赖性TRAF2降解的机制
  • 批准号:
    30971501
  • 项目类别:
    面上项目
  • 资助金额:
    31.0万元
  • 批准年份:
    2009
  • 负责人:
    李联运
  • 依托单位: